Key Updates in CDK4/6 Inhibitors for HR+/HER2- Metastatic Breast Cancer

A panel of medical experts begin a discussion surrounding key updates in treatment and management of HR+/HER2- metastatic breast cancer.

Ryan Haumschild, PharmD, MS, MBA, leads drives a conversation surrounding the impact of CDK4/6 inhibitors in treatment of metastatic breast cancer.

Hormone therapy in metastatic breast cancer management is examined by key opinion leaders.

Heather Moore, CPP, PharmD, BCOP, highlights the impact of pharmacists in adverse effect profile management for CDK4/6 inhibitors.

Rose DiMarco, PharmD, BCPS, BCOP, addresses strategies to maximize patient adherence to CDK4/6 inhibitor therapy.

The pharmacist’s role in addressing treatment failure for patients receiving CDK4/6 inhibitors is examined.

Expert panelists discuss the impact of CDK4/6 inhibitor therapy on progression-free and overall survival.

Jacob Kettle, PharmD, BCOP, joins Drs Haumschild and DiMarco in a conversation surrounding findings from the SONIA trial and their impact on shifting mBC treatment strategies.

Adverse event profiles of several approved CDK4/6 inhibitors are discussed.

Dr Kettle outlines NCCN guideline-directed therapy surrounding CDK4/6 inhibitors.

Medical experts weigh in on the strength of collaborative care and shared decision-making in the management of metastatic breast cancer (mBC).

Social determinants of health create a myriad of obstacles to optimal care for patients receiving treatment for metastatic breast cancer.

Medical experts weigh in on key points of emphasis surrounding medication therapy management for patients diagnosed with mBC

Drs DiMarco and Moore weigh the benefits and barriers associated with clinical pathways in treating patients with mBC.

Dr Kettle provide insights into unmet needs surrounding treatment of metastatic breast cancer.

With their final thoughts, the panelists provide key takeaways from their conversation regarding CDK4/6 inhibitor therapy in treatment of HR+/HER2- metastatic breast cancer.